1_img1424895986.jpg 2_img1424896008.jpg 3_img1424896028.jpg 4_img1424896053.jpg
ГЛЕДФАРМ ЛТД intro pharmacovigilance logo-img
  • 1-img1423128723_img1424877095.jpg
  • 2-img1423128732_img1424877082.jpg
  • 3-img1423128813_img1424877070.jpg
  • 4-img1423128825_img1424877057.jpg
  • analiz111_img1422534233.jpg



Prevention of manifestations of atherothrombosis in adults:

  • patients who have suffered myocardial infarction (the treatment is started after a few days, but not later than 35 days after the occurrence), ischemic stroke (the treatment is started 7 days after, but not later than 6 months after the occurrence), or those with a diagnosed peripheral arterial disease (lesion of the arteries and atherothrombosis of the blood vessels of the lower extremities);

  • in patients with acute coronary syndrome:

– with acute coronary syndrome without elevation of the ST segment (unstable angina or myocardial infarction without a Q-wave), including patients who had stent installed percutaneous coronary angioplasty in combination with acetylsalicylic acid (ASA);

with acute myocardial infarction with ST-segment elevation in combination with acetylsalicylic acid (in patients receiving standard medical therapy for whom thrombolytic therapy is indicated).

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASA is indicated in adult patients with atrial fibrillation who have at least one risk factor for vascular events, who have contraindications to treatment with vitamin K antagonists (VKA) and who have low risk of bleeding, for prevention of atherothrombotic and thromboembolic events, including stroke.

1 tablet contains clopidogrel bisulfate equivalent to clopidogrel 75 mg; 

Antithrombotic agents. Antiaggregants. 

View instructions Dounload instruction
All Preparations